Atara Biotherapeutics

San Francisco, United States Founded: 2012 • Age: 14 yrs Listed
Targeted antibody and T-cell therapeutics are developed for multiple diseases.

About Atara Biotherapeutics

Atara Biotherapeutics is a publicly listed company based in San Francisco (United States) founded in 2012. Targeted antibody and T-cell therapeutics are developed for multiple diseases. Atara Biotherapeutics has raised $52 million across 2 funding rounds from investors including ARE, Kleiner Perkins and Celgene. The company has 153 employees. Its website atarabio.com draws about 16 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

Atara Biotherapeutics was founded in 2012 in San Francisco, United States, within the biotechnology sector. Antibody candidates targeting activin A for ovarian cancer and solid tumors, as well as myostatin for cancer cachexia and muscle loss from fractures, are advanced through the pipeline. Allogeneic T-cell therapies addressing Epstein-Barr virus, cytomegalovirus, and WT1 for various cancers are also pursued. Operations center on therapeutic development for infectious and oncologic conditions.

  • Headquarters San Francisco, United States
  • Employees 153
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website atarabio.com
  • Social LinkedIn X
  • Legal Name Atara Biotherapeutics, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $120.77 M (USD)
    -6.33
    as on Dec 31, 2025
  • Net Profit
    $32.69 M (USD)
    as on Dec 31, 2025
  • EBITDA
    $51.89 M (USD)
    as on Dec 31, 2025
  • Total Equity Funding
    $52M (USD)

    in 2 rounds

  • Latest Funding Round
    $13.5M (USD), Series B

    Jan 2014

  • Investors
    ARE

    & 7 more

  • Employee Count
    153

Funding Insights of Atara Biotherapeutics

Atara Biotherapeutics has successfully raised a total of $52M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $13.5 million completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $52M
  • Total Rounds 2
  • Last Round Series B β€” $13.5M
  • First Round $38.5M

    (Dec 2013)

  • Investors Count 8

All 2 funding rounds of Atara Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2014$13.5MSeries B––
Dec 2013$38.5MSeries B––
Valuation history

8 investors in total: 8 institutional.

Investors in Atara Biotherapeutics

Atara Biotherapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Kleiner Perkins and Celgene.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Mid-stage venture capital investments and support for tech entrepreneurs.
dagventures.com
Life science & tech focused VC firm investing in the US
domainvc.comPrinceton, United States
Early stage investments focused VC firm
acks.com
Venture capital investments are facilitated by Amgen-backed entity.
amgenbd.comThousand Oaks, United States
Venture capital firm investing in early-stage tech startups
1972kleinerperkins.comMenlo Park, United States
Therapies for cancer and inflammatory diseases are developed.
1986celgene.comSummit, United States
ecor1cap.com
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
1994are.comPasadena, United States
Premium access

Investor details for Atara Biotherapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Atara Biotherapeutics

76 people are tracked at Atara Biotherapeutics (44 in leadership, 5 in board & advisors, 27 in team); the tracked headcount is 153.

NameRoleGroup
Pascal Touchon
Chairman of the BoardLeadership
Laurence Hanes Gamelin
VP Drug Safety & PharmacovigilanceLeadership
K. Amar Murugan
EVP & Chief Legal OfficerLeadership
AJ Joshi
EVP & Chief Medical OfficerLeadership
Chris Meyer
Operations Product Lead DirectorLeadership
Hadar Adams
Director, Analytical Development And Quality ControlLeadership
Reddy Guda
Director Of Information TechnologyLeadership
Stephanie Triska
Director, Clinical Quality AssuranceLeadership
Shailender Gunnala
Chief Information OfficerLeadership
Cokey Nguyen
EVP & Chief Scientific & Technical OfficerLeadership
Xianhui Chen
Associate DirectorLeadership
Joel Harris
Senior Director, Intellectual PropertyLeadership
Jill Henrich
EVP & Global Head Regulatory Affairs & QualityLeadership
Wenjin Cao
Associate Director, Quality OperationsLeadership
Paula Kaplan-Lefko
Director Of Regulatory AffairsLeadership
Matt Verbrugge
Senior Director Program ManagementLeadership
Jake Buchholtz
Senior Director, Global OperationsLeadership
Robyn Murphy
Director Clinical Program ManagementLeadership
Amy Gamber
Vice President Of ManufacturingLeadership
Guido Palermo
Sr. Director, External ManufacturingLeadership

56 more people are available in the full profile.

Premium access

Complete people profiles for Atara Biotherapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Atara Biotherapeutics

Atara Biotherapeutics is a publicly listed company on the NASDAQ with ticker symbol ATRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Oct 2014
  • Listed onNASDAQ: ATRA
  • Listed entityAtara Biotherapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS0465132068
  • Share price$9.30 (-0.8% on the day) · 2026-10-13
  • Market capitalisation$93.4M
  • Price to earnings6.9
  • EPS (diluted, trailing year)$-1.40
  • Volume (last session)32,286

Financials of Atara Biotherapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$120.8M$32.7M$51.9M
2024$128.9M-$85.4M-$75.6M
2023$8.6M-$276.1M-$264.4M
2022$63.6M-$228.3M-$260.0M
2021$20.3M-$340.1M-$329.1M
Premium access

Detailed financial statements for Atara Biotherapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Atara Biotherapeutics

4 dated milestones of Atara Biotherapeutics across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded Atara Biotherapeutics is founded.
  2. Funding First funding round of $38.5M.
  3. Funding Latest funding round, Series B, of $13.5M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Atara Biotherapeutics

Atara Biotherapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Atara Biotherapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Atara Biotherapeutics

The website of Atara Biotherapeutics (atarabio.com) receives about 16.1K visits a month and ranks #3,186,600 among all websites worldwide, #4,194 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    16.1K

    ▲ 144.1% vs previous month

  • Unique visitors
    2.8K

    per month

  • Global rank
    #3,186,600

    among all websites

  • Category rank
    #4,194

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Atara Biotherapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
vaxart.com
100%
4.8K#4,483,544View details
ampliphibio.com
ampliphibio.com
98%
–
dynavax.com
97%
11K#2,032,192View details
bellicum.com
96%
1.8K#8,642,421View details
ddn-news.com
ddn-news.com
96%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 15 similar websites and full traffic analytics for Atara Biotherapeutics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 15 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Atara Biotherapeutics (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Atara Biotherapeutics

Premium access

Complete news archive for Atara Biotherapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Atara Biotherapeutics

Atara Biotherapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Atara Biotherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Atara Biotherapeutics is a funded company, having raised a total of $52M across 2 funding rounds to date. The company's 1st funding round was a Series B of $38.5M, raised on Dec 2013.

Atara Biotherapeutics has 153 employees.

Annual revenue of Atara Biotherapeutics is $120.77M as on Dec 31, 2025.

Atara Biotherapeutics was founded in 2012 in San Francisco, United States, within the biotechnology sector. Antibody candidates targeting activin A for ovarian cancer and solid tumors, as well as myostatin for cancer cachexia and muscle loss from fractures, are advanced through the pipeline. Allogeneic T-cell therapies addressing Epstein-Barr virus, cytomegalovirus, and WT1 for various cancers are also pursued. Operations center on therapeutic development for infectious and oncologic conditions.

Atara Biotherapeutics's top competitors include Moderna, BeiGene and Incyte.

Yes, Atara Biotherapeutics is publicly traded on NASDAQ under the ticker symbol ATRA.

Atara Biotherapeutics has 8 investors. Key investors include ARE, Kleiner Perkins, Celgene, EcoR1, and DAG Ventures.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available